Anti-PD1 Therapy in Lynch Syndrome-associated Recurrent Glioblastoma

Abstract

Less than 5% of glioblastomas result from a hereditary syndrome. While not common, they do occur and perhaps may be under-recognized if family history is not known. Now, with more frequent germline testing done as a component of next generation tumor sequencing, it is hypothesized that these hereditary syndromes are better detected. This improved detection is not only beneficial for screening family members and screening the patient for other associated malignancies, but this opens up an opportunity for us as clinicians and scientists to better understand the tumorigenesis of glioblastoma in hereditary syndromes, which in turn may offer individualized treatment regimens.